Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Apr;13(4):513–518. doi: 10.1111/j.1365-2125.1982.tb01413.x

Spironolactone dose-response relationships in healthy subjects.

G T McInnes, R M Perkins, J R Shelton, I R Harrison
PMCID: PMC1402049  PMID: 7066166

Abstract

1 The effect of single oral doses of spironolactone 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and placebo in reversing the urinary electrolyte changes induced by fludrocortisone between 2-10 h and 12-16 h after treatment was examined in healthy subjects. 2 In the two collection periods, there were statistically significant log linear dose-response relationships for sodium excretion (P less than 0.001), potassium excretion (P less than 0.001 and P less than 0.025 respectively) and log10 10 Na/K (P less than 0.001). 3 However, there was evidence that the log spironolactone dose-urinary sodium responses did not increase monotonically, while the relationship for urinary potassium appeared to enter the lower 'plateau' at doses between 100 mg and 200 mg, and when compared to placebo values, potassium excretion was not significantly depressed 12-16 h after treatment (P greater than 0.1). Thus, sodium and potassium responses were dissociated in dose producing maximal effect and in duration of activity, reinforcing the view that functions or the urinary sodium/potassium ratio alone cannot be considered an adequate description of renal antimineralocorticoid activity. 4 Dose-response relationships for all urinary electrolyte variables seem consistently steep and linear between 25 mg and 100 mg of spironolactone, suggesting that, in studies employing this model, the doses of spironolactone should be restricted to this range.

Full text

PDF
513

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DRILL V. A. The aldosterone blocking effects of spirolactones. Jpn J Pharmacol. 1962 Mar;11:77–87. doi: 10.1254/jjp.11.77. [DOI] [PubMed] [Google Scholar]
  2. Ferguson R. K., Turek D. M., Rovner D. R. Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension. Clin Pharmacol Ther. 1977 Jan;21(1):62–69. doi: 10.1002/cpt197721162. [DOI] [PubMed] [Google Scholar]
  3. GANTT C. L. Aldosterone antagonists. N Y State J Med. 1961 Mar 1;61:756–770. [PubMed] [Google Scholar]
  4. GOCHMAN N., GANTT C. L. A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma. J Pharmacol Exp Ther. 1962 Mar;135:312–316. [PubMed] [Google Scholar]
  5. KAGAWA C. M. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. Endocrinology. 1960 Jul;67:125–132. doi: 10.1210/endo-67-1-125. [DOI] [PubMed] [Google Scholar]
  6. Karim A., Zagarella J., Hribar J., Dooley M. Spironolactone. I. Disposition and metabolism. Clin Pharmacol Ther. 1976 Feb;19(2):158–169. doi: 10.1002/cpt1976192158. [DOI] [PubMed] [Google Scholar]
  7. Karim A., Zagarella J., Hutsell T. C., Dooley M. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels. Clin Pharmacol Ther. 1976 Feb;19(2):177–182. doi: 10.1002/cpt1976192177. [DOI] [PubMed] [Google Scholar]
  8. LIDDLE G. W. Sodium diuresis induced by steroidal antagonists of aldosterone. Science. 1957 Nov 15;126(3281):1016–1018. doi: 10.1126/science.126.3281.1016. [DOI] [PubMed] [Google Scholar]
  9. McInnes G. T., Asbury M. J., Shelton J. R., Harrison I. R., Ramsay L. E., Venning G. R., Clarke J. M. Activity of sulfur-containing intermediate metabolites of spironolactone. Clin Pharmacol Ther. 1980 Mar;27(3):363–369. doi: 10.1038/clpt.1980.48. [DOI] [PubMed] [Google Scholar]
  10. McInnes G. T., Harrison I. R., Shelton J. R., Perkins R. M. Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency. Br J Clin Pharmacol. 1981 Nov;12(5):743–747. doi: 10.1111/j.1365-2125.1981.tb01299.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McInnes G. T., Shelton J. R., Asbury M. J., Harrison I. R., Clarke J. M., Ramsay L. E., Venning G. R. Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison. Clin Pharmacol Ther. 1981 Aug;30(2):218–225. doi: 10.1038/clpt.1981.151. [DOI] [PubMed] [Google Scholar]
  12. McInnes G. T., Shelton J. R., Harrison I. R. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate. Clin Pharmacol Ther. 1981 May;29(5):679–686. doi: 10.1038/clpt.1981.95. [DOI] [PubMed] [Google Scholar]
  13. Ochs H. R., Greenblatt D. J., Bodem G., Smith T. W. Spironolactone. Am Heart J. 1978 Sep;96(3):389–400. doi: 10.1016/0002-8703(78)90052-2. [DOI] [PubMed] [Google Scholar]
  14. Papadoyanakis N., Darsinos J., Alexandrou K., Karli J. High doses of spironolactone in the treatment of liver cirrhosis with ascites. Br J Clin Pract. 1972 Jan;26(1):27–32. [PubMed] [Google Scholar]
  15. ROSS E. J. Human assay of electrolyte-active steroids and their antagonists. Clin Sci. 1962 Oct;23:197–202. [PubMed] [Google Scholar]
  16. ROSS E. J., WINTERNITZ W. W. The effect of an aldosterone antagonist on the renal response to sodium restriction. Clin Sci. 1961 Feb;20:143–148. [PubMed] [Google Scholar]
  17. Ramsay L., Asbury M., Shelton J., Harrison I. Spironolactone and canrenoate-K: relative potency at steady state. Clin Pharmacol Ther. 1977 May;21(5):602–609. doi: 10.1002/cpt1977215602. [DOI] [PubMed] [Google Scholar]
  18. Ramsay L., Harrison I., Shelton J., Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther. 1975 Oct;18(4):391–400. doi: 10.1002/cpt1975184391. [DOI] [PubMed] [Google Scholar]
  19. Ramsay L., Shelton J., Harrison I., Tidd M., Asbury M. Spironolactone and potassium canrenoate in normal man. Clin Pharmacol Ther. 1976 Aug;20(2):167–177. doi: 10.1002/cpt1976202167. [DOI] [PubMed] [Google Scholar]
  20. Sadée W., Schröder R., von Leitner E., Dagcioglu M. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure. Eur J Clin Pharmacol. 1974;7(3):195–200. doi: 10.1007/BF00560381. [DOI] [PubMed] [Google Scholar]
  21. Sakauye C., Feldman D. Agonist and antimineralocorticoid activities of spirolactones. Am J Physiol. 1976 Jul;231(1):93–97. doi: 10.1152/ajplegacy.1976.231.1.93. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES